Safety Reporting Carrie Bayliss.

Slides:

Advertisements

Similar presentations

The HRPP FYI Process and the UPIRSO/SAE Review Sheet An IRB Infoshort February 2014.

Advertisements

Adverse Events and Serious Adverse Events

Safety Reporting IN Clinical Trials

New Trials If you are seeking a collaboration with the UCL CCTU we require you to apply: At least 3 months before the application deadline By using the.

Chicken Soup for the Busy Coordinator Aug Scenario: Aim: Randomised, double-blind, phase III clinical trial to compare the safety and efficacy of.

Adverse Event Reporting. Reporting Adverse Events Adverse Events (AEs) are “... any untoward medical occurrence in a subject that was not previously identified.

Pharmacovigilance Lindsey Connery Pharmacovigilance Manager, Cancer Research UK Clinical Trials Unit, Glasgow.

Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.

Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.

Paula Nicholson Research Facilitator

Continuing Review VA Requirements Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst Program for Research Integrity Development and Education (PRIDE)

SAE Report CTT21 V To:Quality Assurance Research & Development 34 Hyde Terrace LS2 9LN Date:…………………………….. Fax To:+44(0) From (name):………………………..

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Adverse Event Reporting Catherine Dillon.

Adverse Event Reporting.

H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.

1 MRC SUPREMO (BIG 2-04) Selective Use of Postoperative Radiotherapy aftEr MastectOmy Phase III randomised trial of chest wall RT in intermediate- risk.

Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.

ICH V2 An FDA Update Susan Lu Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.

Division of AIDS Data Interchange. Division of AIDS Data Interchange Agenda.

ACCREDITED CONSULTANTS PVT LTD. (ACPL) WELCOMES YOU Your PHARMACOVIGILANCE PARTNER.

Adverse Event Reporting & SAE Reporting for Investigators Trial Number: (POLO-AML-2) Date of training:23 February 2013 Trainer: Deepa Sachdev Venue:Investigator.

EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.

RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.

Serious Adverse Event Reporting Start-up Meeting March 25, 2010 Kingston, ON.

Role of Site Investigator Ensure subject safety is protected & well-managed Full compliance with requirements of Good Clinical Practice (GCP) Conduct the.

ACRIN CV Committee ACRIN PDRC ACRIN PA 4008 Protocol and Regulatory Requirements Patricia Atkinson, Quality Control Monitor.

D3 ) Not Recovered d5) Fatal Was a post-mortem undertaken?YesNo Was the SAE ongoing at time of death from other cause? Yes No d d m m y y y y d1) Recovered.

Site Set-up and Conduct Caroline O’Leary and Carrie Bayliss.

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Unanticipated Problems 15 th FERCAP International Conference 24 Nov 15 Nagasaki, Japan.

1 SAE Centralized Report and Review Process April 2012.

Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.

HOW TO SCREEN PATIENTS AND BOOK THE BASELINE VISIT APPOINTMENT?

REPORTING ADVERSE EVENTS AND COMPLETING THE REPORT FORM

Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP

Introduction Review and proper registration of Human Gene Transfer protocols is very complex. A protocol goes through rigorous review by multiple Committees.

HOW TO ENTER EARLY WITHDRAWAL DATA

Reportable Events Emory IRB 9/11/2014.

Safety Reporting V6.0 17/01/17.

MAINTAINING THE INVESTIGATOR’S SITE FILE

IRB reporting updates.

Assessing expectedness of an adverse event

Reportable Events & Other IRB Updates February 2017

Safety Reporting Nichol McBee, MPH, CCRP.

Expedited Adverse Event Reporting Requirements

Adverse Event Reporting: Trials and Tribulations

Remote Monitoring of Adverse Events

Pharmacovigilance in clinical trials

Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP

UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.

Expedited Adverse Event Reporting Requirements

*Continue on SAE supplemental page CTT21 A if more space is required

SPECTRE (U233) Combined SuPpression of cholEsterol bioavailability and androgen deprivation therapy to treat CastraTion Resistant prostatE cancer INITIATION.

Remote Monitoring of Adverse Events

Combination products The paradigm shift

SERIOUS ADVERSE EVENTS REPORTING

Single Subject Protocol Modification

Getting a Study Done at Jefferson:

Myeloma UK Clinical Trial Network (CTN)

HOW TO ENTER BASELINE DATA

CONDUCTING THE TRIAL AT

MAINTAINING THE INVESTIGATOR’S STUDY FILE

WHAT TO DO IF A PATIENT DEVELOPS AN UNEXPECTED PROBLEM?

Screening Epoch Disposition eCRF

Clinical Trial Development: RA’s Role, OEWG, and IRB Submissions Martha Heckel Protocol Associate, ACRIN Dept. of Protocol Development & Regulatory.

Key Value Indicators (KVIs)

E-CRF Overview Oracle® Clinical Remote Data Capture Training (Version 4.6 HTML) e-CRF Completion John McDonach Manager CDM, PPD.

Dr Tim England TICH-2 SAE adjudicator

Policy on Prompt Reporting

Protocol Approval Criteria

Serious Adverse Event Reconciliation

Presentation transcript:

Safety Reporting Carrie Bayliss

What is reportable? Expedited Reporting: SARs SUSARs Pregnancy in female participants Scheduled Review: SAEs routinely captured within the following systems HES, IDS, PEDW, HSNI and ONS and reviewed at least 6 monthly for SAE line listing

SARs Any serious adverse event that has a reasonable causal relationship to the IMP. Reasonable defined as Definitely, Probably or Possibly related. Reportable to the Simplified Trial Office within 24 hours of first notification/awareness to anyone within the trial team Simplified SAR Reporting Form to be completed as fully as possible SAR Reporting Form must be countersigned by the PI but doesn’t need to be completed prior to submission of the initial report if this will impact on the 24 hour notification timeline

SUSARs Expectedness assessment to be conducted against the Reference Safety Information: Section 4.8 of the Fultium –D3 (colecalciferol 20,000IU capsules) from Internis Pharma Limited. If not specifically listed in the RSU, the event is Unexpected Reportable immediately (within 24 hours) Complete SAR Reporting Form and submit to the Simplified Trial Office Timeline for follow-up information will be confirmed by the Simplified Trial Office Any queries regarding (potential) SUSARs should be raised with the Simplified Trial Office immediately

SAR Reporting Form

SAR Reporting Form cont.

Pregnancy Reporting Only for female participants (not partners) Reportable to the Simplified Trial Office within 7 days of first notification/awareness to the trial team Pregnancy only reportable if the patient conceived whilst receiving active treatment with colecalciferol – ie if the patient ceased treatment prior to conceiving this is not reportable. Where there is ambiguity between treatment cessation and conception date, report as a trial pregnancy

Pregnancy Reporting Form

Pregnancy Reporting Form cont.

Reporting Form Submission Completed Reporting Forms submitted to the Simplified Trial Office: SARs & SUSARs – within 24 hours Pregnancy – within 7 days Submission by fax: 01223 256763 or Submission by email: add-tr.Simplified@nhs.net Each email or fax coversheet should state in the subject line (email) or main body (fax) whether the reporting form is for a SAR, SUSAR or pregnancy All reports will be acknowledged within 48 hours. For SUSARs the acknowledgement will also state the 7 or 15 day regulatory deadline

SAE Line Listings SAE Line Listings will be generated by the Simplified Trial Office from review of routinely collected data for the trial Generated at least every 6 months Reviewed by the CI and any queries raised with the PI Will contribute to the safety data reported to the MHRA and REC via the DSUR DSUR will be provided to PIs for inclusion in the ISF